Form 4: ORIC Pharmaceuticals CFO Sells Over 3,000 Shares Under Pre-Arranged Trading Plan

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, has sold 3,300 shares of common stock for approximately $33,000 through a pre-established Rule 10b5-1 trading plan.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported the sale of 3,300 shares of common stock.
• The sales occurred on June 10, 2025, and June 11, 2025, at prices ranging from $10.00 to $10.01 per share.
• Specifically, 324 shares were sold at $10.00 on June 10, 2025.
• On June 11, 2025, two separate transactions occurred: 1,276 shares were sold at $10.00, and 1,700 shares were sold at $10.01.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Piscitelli on December 30, 2024.
• Following these sales, Mr. Piscitelli beneficially owns 102,117 shares of Oric Pharmaceuticals common stock.
• The reported beneficial ownership includes 1,553 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, although mitigated by the fact that it was a pre-planned transaction under a Rule 10b5-1 plan, suggesting it was not a reaction to new adverse information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on December 30, 2024, indicating that the transactions were scheduled in advance and not a reaction to recent negative company developments.

Negatives

• The Chief Financial Officer selling shares, even under a 10b5-1 plan, can be perceived negatively by investors as it may suggest a lack of confidence in the company's near-term stock price appreciation, or simply a desire to diversify personal holdings.

Risks

• Insider selling, even if planned, can sometimes lead to negative market sentiment or increased scrutiny from investors, potentially impacting the company's stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is specific to an insider stock transaction and does not provide broader insights into industry trends or competitive landscape. It reflects an individual executive's financial planning rather than a strategic corporate move.

Stakeholder Impact

• Shareholders may interpret the CFO's sale as a signal regarding the company's valuation or future prospects, potentially influencing their investment decisions.

Next Steps

• Investors may monitor future insider transactions by Oric Pharmaceuticals executives to gauge ongoing sentiment and ownership changes.

Key Dates

Recommendation

Keywords

Oric Pharmaceuticals, ORIC, Dominic Piscitelli, Chief Financial Officer, CFO, Insider Trading, Form 4, SEC Filing, Stock Sale, Rule 10b5-1, Equity Transaction, Common Stock